Evaxion reports EVX-01 induces strong immune responses in phase 2 melanoma trial
EVAX•Evaxion reported strong immune responses to its personalized cancer vaccine EVX-01 in patients with advanced melanoma. The results are due to be presented November 6-7, 2026, at the Society for Immunotherapy of Cancer annual meeting.
1. Phase 2 findings
Evaxion announced Phase 2 data showing strong immune responses to EVX-01 in patients with advanced melanoma. The company said the findings supported its AI platform’s ability to select vaccine targets likely to generate strong immune responses.
2. Presentation and follow-up
The results will be presented November 6-7, 2026, at the Society for Immunotherapy of Cancer annual meeting in Phoenix. Previously presented three-year follow-up data showed sustained immune and clinical responses.
